Table 4.

Association of female menopausal hormone use with endometrial cancer among women age ≥40 years, 1995–2013^a

				Age adjusted^b		Multivariable adjusted^c
Exposure	Cases	Person-years	Rate^d	IRR	95% CI	IRR	95% CI
Estrogen-only FMH use^e
Never^f	155	277,471	55.9	1.00	Referent	1.00	Referent
Ever	16	12,130	131.9	1.28	0.76–2.17	1.32	0.78–2.23
Former	9	8,882	101.3	0.86	0.44–1.70	0.87	0.44–1.72
Years since last use
1–9	5	6,230	80.3	0.71	0.29–1.73	0.73	0.30–1.80
≥10	4	2,637	151.7	1.19	0.43–3.26	1.15	0.42–3.17
Current	7	3,248	215.5	3.45	1.56–7.65	3.78	1.69–8.43
Duration (years)
1–4	13	10,668	121.9	1.22	0.68–2.16	1.25	0.70–2.23
≥5	3	1,271	236.0	1.85	0.58–5.89	1.90	0.59–6.09
Estrogen + progestin FMH use^g
Never^f	155	277,471	55.9	1.00	Referent	1.00	Referent
Ever	25	28.602	87.4	0.71	0.46–1.11	0.82	0.53–1.28
Former	15	17,790	84.3	0.55	0.32–0.96	0.63	0.36–1.09
Years since last use
1–9	9	13,586	66.2	0.46	0.23–0.92	0.53	0.27–1.06
≥10	6	4,180	143.5	0.79	0.34–1.83	0.86	0.37–2.01
Current	10	10,812	92.5	1.29	0.65–2.56	1.55	0.78–3.11
Duration
1–4	16	20,356	78.6	0.71	0.42–1.20	0.79	0.47–1.35
≥5	9	7,304	123.2	0.81	0.41–1.61	0.99	0.49–1.98
Pattern of progestin use^g
Never used FMH^f	177	186,113	95.1	1.00	Referent	1.00	Referent
<2 wk/mo.	11	7,836	140.4	1.14	0.62–2.11	1.29	0.70–2.39
2–3 wk/mo.	0	5,080	0.0	0.00	—	0.00	—
Continuous	8	9,442	84.7	0.64	0.31–1.31	0.74	0.36–1.50
Other	1	1,390	71.9	0.62	0.09–4.44	0.63	0.09–4.49
Progestin-only FMH use^e^,^g
Never^f	155	277,471	55.9	1.00	Referent	1.00	Referent
Ever	8	7,366	108.6	1.74	0.85–3.56	1.51	0.73–3.09

↵^aAnalysis restricted to women ≥40 years of age, not taking oral contraceptives, with known menopause status, and not reporting use of multiple FMH types.
↵^bAge-adjusted model stratified by age and study period.
↵^cMultivariable model stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, smoking, BMI, and vigorous physical activity.
↵^dCrude rate per 100,000 person-years.
↵^eAdditionally adjusted for estrogen plus progestin FMH use.
↵^fNever reported any FMH use.
↵^gAdditionally adjusted for estrogen-only FMH use.